Novacyt S.A. Director/PDMR Shareholding (1866N)
May 18 2020 - 3:00AM
UK Regulatory
TIDMNCYT
RNS Number : 1866N
Novacyt S.A.
18 May 2020
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholdings
Paris, France and Camberley, UK - 18 May 2020 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that it has been notified that, on
15 May 2020, the following Directors purchased ordinary shares of
EUR1/15 each in the Company (the "Ordinary Shares"):
Director Title Number of Price paid Resultant % of issued
Ordinary per Ordinary beneficial share capital
Shares purchased Share holding
Chief Executive
Graham Mullis Officer 9,493 310 p 61,631 0.09%
----------------- ------------------ -------------- ------------ ---------------
Non-Executive
Director
James Wakefield & Chairman 20,000 304.9p 36,839 0.05%
----------------- ------------------ -------------- ------------ ---------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
Graham Mullis, Chief Executive
Officer
-------------------------------- ---------------------------------
2. Reason for the Notification
-------------------------------------------------------------------
a) Position/status See 1(a) - classified as
a PDMR of the Company
-------------------------------- ---------------------------------
b) Initial notification/ Amendment Initial Notification
-------------------------------- ---------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Novacyt S.A.
-------------------------------- ---------------------------------
b) LEI 213800BWAC2BF295EG28
-------------------------------- ---------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Financial ordinary shares of EUR1/15
instrument, type of instrument each
-------------------------------- ---------------------------------
Identification code FR0010397232
-------------------------------- ---------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- ---------------------------------
c) Price(s) and volume(s) Price Volume
310 pence 9,493
-------
-------------------------------- ---------------------------------
d) Aggregated information:
-- Aggregated volume N/A Single transaction as
-- Price above Price Volume
310 pence 9,493
-------
-------------------------------- ---------------------------------
e) Date of the transaction
15 May 2020
-------------------------------- ---------------------------------
f) Place of the transaction AIM
-------------------------------- ---------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
James Wakefield, Non-Executive
Director & Chairman of the
Board
-------------------------------- --------------------------------------
2. Reason for the Notification
------------------------------------------------------------------------
a) Position/status See 1(a) - classified as
PDMRs of the Company
-------------------------------- --------------------------------------
b) Initial notification/ Amendment Initial Notification
-------------------------------- --------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name Novacyt S.A.
-------------------------------- --------------------------------------
b) LEI 213800BWAC2BF295EG28
-------------------------------- --------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------
a) Description of the Financial ordinary shares of EUR1/15
instrument, type of instrument each
-------------------------------- --------------------------------------
Identification code FR0010397232
-------------------------------- --------------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- --------------------------------------
c) Price(s) and volume(s) Price Volume
a) 304.9 pence 20,000
-------
-------------------------------- --------------------------------------
d) Aggregated information:
-- Aggregated volume N/A single transaction as
-- Price above Price Volume
a) 304.9p 20,000
-------
-------------------------------- --------------------------------------
e) Date of the transaction
15 May 2020
-------------------------------- --------------------------------------
f) Place of the transaction AIM
-------------------------------- --------------------------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 47
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website: www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHGPUAAAUPUUMR
(END) Dow Jones Newswires
May 18, 2020 04:00 ET (08:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024
